ArticleMolecular imaging and radionuclide therapy2021
Physiological Biodistribution of
Article in Molecular imaging and radionuclide therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Transitioning from CA to NCAPhysical and engineering sciences in medicine · 2026Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- PET/CT contouring techniques in neuroendocrine neoplasms: a state-of-the-art scoping review.EJNMMI reports · 2026Review
- Review
- Diagnosis: Phosphaturic mesenchymal tumor.Skeletal radiology · 2025Article
- Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review.Annals of nuclear medicine · 2025Review
- Physiological bio-distribution ofAnnals of nuclear medicine · 2025Article
- Radioactivity levels in the saliva of patients undergoing targeted radioligand therapy with [Clinical oral investigations · 2025Article
- Article
- Novel Detection of Pleomorphic Adenomas via Analysis ofCancers · 2024Article
- Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Semiquantitative evaluation ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Role of Exendin-4 Functional Imaging in Diagnosis of Insulinoma: A Systematic Review.Life (Basel, Switzerland) · 2023Review
- PET/CT and PET/MRI in neuroendocrine neoplasms.Abdominal radiology (New York) · 2022Review
- Article
- Normal Variants, Pitfalls and Artifacts in Ga-68 DOTATATE PET/CT Imaging.Frontiers in nuclear medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Somatostatin is an endocrine peptide hormone that regulates neurotransmission and cell proliferation by interacting with G protein-coupled somatostatin receptors (SSTRs). SSTRs are specific molecular targets of several radiotracers for neuroendocrine tumor (NET) imaging. Gallium-68 ( Methods: A total of 617 consecutive Results: The highest uptake of Conclusion: Our study shows the biodistribution pattern of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.